Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with <scp>COVID</scp>‐19 in clinical practice during the Omicron (<scp>BA</scp>.1 and <scp>BA</scp>.2) pandemic-Reference-Cited by-同舟云学术

Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID‐19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic

Published:2023-07-03 Issue:6 Volume:27 Page:1064-1069
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Kikuchi Kan¹,Nangaku Masaomi²,Ryuzaki Munekazu³,Yamakawa Tomoyuki⁴,Ota Yoshihiro⁵,Hanafusa Norio⁶,Sakai Ken⁷,Kanno Yoshihiko⁸,Ando Ryoichi⁹,Shinoda Toshio¹⁰,Wakino Shu¹¹,Nakamoto Hidetomo¹²,Takemoto Yoshiaki¹³,Akizawa Tadao¹⁴^ORCID,

Affiliation:

1. Division of Nephrology Shimoochiai Clinic Tokyo Japan

2. Division of Nephrology and Endocrinology The University of Tokyo Graduate School of Medicine Tokyo Japan

3. Department of Nephrology Tokyo Saiseikai Central Hospital Tokyo Japan

4. Kidney Center Shirasagi Hospital Osaka Japan

5. Nagoya Memorial Hospital Nagoya Japan

6. Department of Blood Purification Tokyo Women's Medical University Tokyo Japan

7. Department of Nephrology Toho University Faculty of Medicine Tokyo Japan

8. Department of Nephrology Tokyo Medical University Tokyo Japan

9. Department of Nephrology Medical Group Ishikawa Tokyo Japan

10. Advanced Course for Clinical Engineering Teikyo University Junior College Tokyo Japan

11. Department of Nephrology Institute of Biomedical Sciences, Tokushima University Graduate School Tokushima Japan

12. Department of General Internal Medicine Saitama Medical University Saitama Japan

13. Department of Urology, Graduate School of Medicine Osaka Metropolitan University Osaka Japan

14. Division of Nephrology, Department of Medicine Showa University School of Medicine Tokyo Japan

Abstract

AbstractIntroductionIn the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis patients.MethodsDialysis patients with confirmed SARS‐CoV‐2 during the COVID‐19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared.ResultsA total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group (p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID‐19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively).ConclusionSotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important.

Publisher

Wiley

Subject

Nephrology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.14033

Reference12 articles.

1. COVID ‐19 of dialysis patients in Japan: Current status and guidance on preventive measures

2. Incidence and Clinical Impacts of COVID-19 Infection in Patients with Hemodialysis: Systematic Review and Meta-Analysis of 396,062 Hemodialysis Patients

3. Effectiveness of SARS‐CoV ‐2 vaccines on hemodialysis patients in Japan: A nationwide cohort study

4. Severity of COVID-19 after Vaccination among Hemodialysis Patients

5. Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan;Infectious Diseases and Therapy;2024-01

2. 2．感染症;Nihon Toseki Igakkai Zasshi;2023